Global Preclinical Oncology CRO Market Growth (Status and Outlook) 2025-2031

According to this study, the global Preclinical Oncology CRO market size will reach US$ 1086 million by 2031.

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.

The industry"s leading producers are Crown Bioscience, Charles River and ICON, with revenues of 18.32 percent, 13.86 percent and 9.13 percent in 2019.

LPI (LP Information)' newest research report, the “Preclinical Oncology CRO Industry Forecast” looks at past sales and reviews total world Preclinical Oncology CRO sales in 2024, providing a comprehensive analysis by region and market sector of projected Preclinical Oncology CRO sales for 2025 through 2031. With Preclinical Oncology CRO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Preclinical Oncology CRO industry.

This Insight Report provides a comprehensive analysis of the global Preclinical Oncology CRO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Preclinical Oncology CRO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Preclinical Oncology CRO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Preclinical Oncology CRO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Preclinical Oncology CRO.

This report presents a comprehensive overview, market shares, and growth opportunities of Preclinical Oncology CRO market by product type, application, key players and key regions and countries.

Segmentation by Type:
Blood Cancer
Solid Tumors
Other

Segmentation by Application:
In Vitro
In Vivo

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Crown Bioscience
Charles River Laboratory
ICON Plc.
Eurofins Scientific
Taconic Biosciences
Covance
EVOTEC
The Jackson Laboratory
Wuxi AppTec.
MI Bioresearch, Inc.
Champion Oncology, Inc.
Xentech

Please note: The report will take approximately 2 business days to prepare and deliver. Show more